INVIVO THERAPEUTICS HLDGS CO's ticker is and the CUSIP is 46186M605. A total of 14 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $6,128 | -27.9% | 8,395 | +10.6% | 0.00% | – |
| Q3 2023 | $8,504 | -14.8% | 7,593 | +2.7% | 0.00% | – |
| Q2 2023 | $9,978 | +498800.0% | 7,391 | +314.3% | 0.00% | – |
| Q1 2023 | $2 | -83.3% | 1,784 | -65.3% | 0.00% | – |
| Q4 2022 | $12 | -99.8% | 5,147 | +193.8% | 0.00% | – |
| Q3 2022 | $7,000 | +75.0% | 1,752 | +95.5% | 0.00% | – |
| Q2 2022 | $4,000 | – | 896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 222,000 | $521,700 | 0.01% |
| Renaissance Technologies | 10,125 | $24 | 0.00% |
| ROYAL BANK OF CANADA | 69 | $0 | 0.00% |
| VANGUARD GROUP INC | 16,946 | $39,823 | 0.00% |
| Colonial Trust Advisors | 2 | $5 | 0.00% |
| WELLS FARGO & COMPANY/MN | 13 | $31 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| UBS Group AG | 4,267 | $10,027 | 0.00% |
| IFP Advisors, Inc | 1 | $1 | 0.00% |
| Sugarloaf Wealth Management, LLC | 1 | $2 | 0.00% |